Press Releases
2013
May 23, 2013
Spectral Diagnostics Provides Update on Results of Annual and Special Meeting
May 15, 2013
Spectral Announces First Quarter 2013 Results
May 7, 2013
Spectral Appoints Vice President of Sales and Marketing
April 16, 2013
Spectral Diagnostics Adopts New By-Laws Which Contain Advance Notice Provisions
April 2, 2013
Spectral Diagnostics Closes $5.6 Million Offering
March 27, 2013
Spectral Announces Fourth Quarter and Fiscal 2012 Results
March 18, 2013
Spectral Diagnostics Increases Offering to $5.6 Million
March 7, 2013
Toray Industries Makes $5 Million Strategic Investment in Spectral Diagnostics
February 4, 2013
Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board
2012
December 5, 2012
Spectral Announces Enrollment Milestone for its Euphrates Trial
November 14, 2012
Spectral Announces Third Quarter 2012 Results
November 9, 2012
Spectral Announces New Clinical Data is Being Presented at International Sepsis Forum
September 26, 2012
FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
September 4, 2012
Spectral to Present at Rodman & Renshaw Annual Global Investment Conference on September 10 - Company will also attend World Sepsis Day in New York on September 13
Spectral’s Presentation at Rodman & Renshaw 14th Annual Healthcare Conference
August 16, 2012
Spectral and Toray Expand EAA™/PMX Theranostic to Saudi Arabia and Turkey
August 14, 2012
Spectral Announces Second Quarter 2012 Results
June 20, 2012
Spectral Diagnostics Provides Update on Euphrates Trial
June 12, 2012
Spectral Diagnostics to Present at Bloom Burton & Co. Healthcare Investor Conference
May 17, 2012
Spectral Diagnostics to Present at BioFinance 2012
May 15, 2012
Spectral Announces First Quarter 2012 Results
March 16, 2012
Spectral Announces Fourth Quarter and 2011 Results
January 11, 2012
Spectral Begins Trading on OTCQX
January 4, 2012
Spectral Diagnostics Provides Corporate Update
2011
December 5, 2011
Op-Ed by Spectral Diagnostics CEO in The Globe and Mail
November 11, 2011
Spectral Diagnostics Inc. Announces Normal Course Issuer Bid
November 10, 2011
Spectral Announces Third Quarter Results
October 25, 2011
Spectral to Expand its Phase III Sepsis Trial to Canadian Sites
September 28, 2011
Spectral's Endotoxin Activity Assay Featured in Major Publication
September 9, 2011
Medwell Capital and Spectral Diagnostics Announce Completion of Plan of Arrangement
September 6, 2011
Spectral to Present at Rodman & Renshaw Annual Global Investment Conference on September 13
August 29, 2011
Medwell Capital and Spectral Diagnostics announce court approval of Plan Of Arrangement and set closing and record date for completion
August 26, 2011
Spectral Shareholders Approve Previously Announced $10 Million Private Placement
August 11, 2011
Spectral Announces Second Quarter Results
August 3, 2011
Spectral Diagnostics Issues Corporate Update
June 28, 2011
Medwell Capital and Spectral Diagnostics Announce Plan of Arrangement
May 19, 2011
Spectral Diagnostics to Present at BioFinance 2011
May 12, 2011
Spectral Announces First Quarter Results
May 5, 2011
Spectral Achieves Important Milestone in its Pivotal U.S. Clinical Trial for Sepsis
April 11, 2011
Spectral Diagnostics Refiles Third Quarter Unaudited Interim Financial Statements
March 28, 2011
Medwell Capital and a Consortium of Buyers Acquire Spectral Diagnostic Shares from GrowthWorks Canadian Fund
March 10, 2011
Spectral Diagnostics Announces Fourth Quarter and 2010 Year End Results
News and Media
2010
December 31, 2010
Spectral Diagnostics Completes Conversion of Promissory Notes
November 22, 2010
Spectral Obtains Exclusive Canadian Distribution Rights for Toraymyxin™
November 15, 2010
Spectral Announces Third Quarter 2010 Results
October 19, 2010
Spectral Initiates U.S. Pivotal Trial of Toraymyxin™ in Septic Shock
September 13, 2010
Spectral to Present at Rodman & Renshaw Annual Global Investment Conference on September 13
Spectral's Rodman & Renshaw Presentation
August 12, 2010
Spectral Announces Second Quarter 2010 Results
June 23, 2010
Spectral Receives McMaster Industry Partner of the Year Award for Aptamer Discovery Research
May 14, 2010
Spectral Announces First Quarter Financial Results
March 11, 2010
Spectral Announces 2009 Results
March 10, 2010
Spectral Appoints Two New Board Members
March 3, 2010
Spectral Closes $19.5 Million Private Placement Financing
March 2, 2010
Spectral Granted IDE Approval by U.S. FDA to Conduct Pivotal Trial for Toraymyxin™
February 26, 2010
Spectral Shareholders Approve $19.5 Million Private Placement Financing
February 3, 2010
Spectral Increases Private Placement Financing to $19.5 Million
2009
December 17, 2009
Spectral Diagnostics Raises $14 Million and Enters into Strategic Collaboration with BIOMS Medical to Commercialize Treatment for Sepsis
Spectral & BioMS Audiocast View a slide presentation and audio recording by Dr. Paul Walker, President and CEO of Spectral and Mr. Kevin Giese, President and CEO of BioMS Medical where they discuss this collaboration and the opportunity for Toraymyxin™ in the treatment of severe sepsis.
November 12, 2009
Spectral Announces Third Quarter 2009 Results
August 13, 2009
Spectral Appoints New Board Member
August 13, 2009
Spectral Announces Second Quarter 2009 Results
May 14, 2009
Spectral Announces First Quarter 2009 Results